Immunic (NASDAQ:IMUX) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Immunic (NASDAQ:IMUX - Free Report) in a report released on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $17.00 target price on the stock.

IMUX has been the topic of a number of other reports. William Blair initiated coverage on shares of Immunic in a research report on Tuesday, March 25th. They set an "outperform" rating on the stock. B. Riley restated a "buy" rating and issued a $6.00 price target on shares of Immunic in a report on Wednesday, April 16th. StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a report on Thursday, March 20th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Immunic in a research note on Tuesday, April 15th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $13.20.

Immunic Price Performance

Shares of Immunic stock traded down $0.02 during trading on Wednesday, hitting $1.14. 828,965 shares of the company were exchanged, compared to its average volume of 695,185. The firm has a market capitalization of $108.75 million, a P/E ratio of -0.93 and a beta of 1.73. The firm's fifty day moving average price is $1.08 and its 200 day moving average price is $1.11. Immunic has a 1-year low of $0.83 and a 1-year high of $2.11.

Hedge Funds Weigh In On Immunic

Several hedge funds have recently made changes to their positions in IMUX. Jane Street Group LLC grew its position in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock valued at $116,000 after purchasing an additional 38,553 shares in the last quarter. HB Wealth Management LLC bought a new position in shares of Immunic in the 4th quarter valued at about $81,000. State Street Corp increased its position in shares of Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company's stock valued at $276,000 after acquiring an additional 11,642 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Immunic by 45.6% during the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock worth $567,000 after acquiring an additional 177,542 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Immunic during the third quarter valued at approximately $50,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.